OncoOne R&D
Vienna, Austria
Dr. Christine Landlinger has been working in the biotech space for over a decade. She spent ten years at AFFiRiS where she was leading preclinical activities for the development of active immunotherapies with a focus on neurodegenerative and cardiovascular diseases. In 2019, she joined PhagoMed, at present BioNTech Austria, a biotech company developing pharmaceuticals to treat bacterial infections. At OncoOne, she serves as the Director of Preclinical and is the Project Lead for Inflammation oxMIF mAb ON104.
Christine studied microbiology at the University in Vienna (Austria) and Lund (Sweden), holds a PhD in molecular biology, and was a postdoctoral fellow at the Institute of Medical Biochemistry and the Children’s Cancer Research Institute in Vienna.
Disclosure information not submitted.
Saturday, November 12, 2022
1:00 PM – 3:00 PM Eastern Time
